aspirin protect 300 mg gastrorezistentne tablete
bayer d.o.o. - acetilsalicilna kislina - gastrorezistentna tableta - acetilsalicilna kislina 300 mg / 1 tableta - acetilsalicilna kislina
aspirin plus c 400 mg/240 mg šumeče tablete z okusom pomaranče
bayer d.o.o. - acetilsalicilna kislina; askorbinska kislina (vitamin c) - šumeča tableta - acetilsalicilna kislina 400 mg / 1 tableta askorbinska kislina (vitamin c)240 mg / 1 tableta; askorbinska kislina (vitamin c) 240 mg / 1 tableta - acetilsalicilna kislina, kombinacije brez psiholeptikov
aspirin 500 mg tablete
bayer d.o.o. - acetilsalicilna kislina - tableta - acetilsalicilna kislina 500 mg / 1 tableta - acetilsalicilna kislina
aspirin plus c 400 mg/240 mg šumeče tablete
bayer d.o.o. - acetilsalicilna kislina; askorbinska kislina (vitamin c) - šumeča tableta - acetilsalicilna kislina 400 mg / 1 tableta askorbinska kislina (vitamin c)240 mg / 1 tableta; askorbinska kislina (vitamin c) 240 mg / 1 tableta - acetilsalicilna kislina, kombinacije brez psiholeptikov
jentadueto
boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - zdravljenje odraslih bolnikov z tipa 2 sladkorna bolezen:jentadueto je indicirano kot dodatek k dieti in telesni za izboljšanje glycaemic nadzor pri odraslih bolnikih, neustrezno nadzorovano na maksimalno dopustne odmerek metforminom sam, ali tistih, ki se že zdravijo z kombinacijo linagliptin in metforminom. jentadueto je navedeno v kombinaciji z sulfonil sečnine (i. trojna kombinacija terapija), kot dopolnilo prehrane in vadbe pri odraslih bolnikih, neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine.
vipdomet
takeda pharma a/s - alogliptin benzoata, metformin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trojna kombinacija terapija), kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor pri bolnikih, pri insulina na stabilen odmerek in metforminom sam ne zagotavljajo ustrezne glycaemic nadzor.
eprocliv 50 mg/1000 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.